Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Aug 14 · inside the Ichimoku cloud · RSI 48 · MACD above its signal · at its 52-week high
None of the 29 investors followed here reported a position in ATTBF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ATTBF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ATTBF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -90.0 | 200.0 | 0.0 | 0.0 | 0.0 | 0.0 | −70.0% |
| 2024 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2023 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 900.0 | 0.0 | +900.0% |
| 2022 | 0.0 | 0.0 | 9900.0 | -99.0 | 0.0 | 0.0 | 0.0 | 400.0 | 100.0 | -90.0 | 0.0 | 0.0 | −0.0% |
| 2021 | 17.6 | 29.3 | 31.6 | -32.8 | -17.9 | -1.4 | -26.8 | 0.5 | -1.0 | -59.6 | -97.5 | -90.0 | −99.9% |
| 2020 | 195.6 | -36.8 | -36.9 | 43.4 | 12.5 | 1.8 | -10.9 | 12.3 | -24.1 | 10.6 | -5.5 | 81.2 | +177.8% |
| 2019 | 12.4 | -21.5 | -27.7 | 18.7 | -14.7 | -20.5 | -9.9 | -19.4 | -10.4 | -18.2 | -42.6 | -47.1 | −91.7% |
| 2018 | -1.5 | -24.7 | -41.5 | -17.5 | -5.0 | -11.5 | -16.3 | 43.5 | -10.8 | -30.2 | -23.7 | -26.0 | −87.3% |
| 2017 | -7.7 | 51.0 | -13.6 | 46.6 | -21.1 | -27.9 | -0.8 | 9.1 | 30.0 | -16.7 | 71.8 | 90.8 | +285.8% |
| 2016 | -7.3 | -14.8 | 10.8 | -9.7 | -21.1 | -6.0 | -0.7 | -22.9 | 131.5 | 165.8 | -21.7 | 6.2 | +129.7% |
| 2015 | -52.0 | 93.1 | -16.2 | -8.2 | -20.6 | -44.1 | 9.5 | -13.5 | -13.1 | 61.4 | -4.0 | -20.6 | −67.9% |
| 2014 | -27.2 | -9.1 | -10.7 | -23.4 | -37.3 | -9.5 | -21.1 | −79.7% |
No analyst coverage for this instrument.
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
No recent headlines.